Vorasidenib and its potential for brain tumour treatment has made the headlines again. You may recall the phase III INDIGO study showed that Vorasidenib may help some people with grade 2 glioma live longer without brain tumour growth. Vorasidenib targets specific genetic changes called IDH mutations that are commonly found in grade 2 gliomas, which mainly affect people who are young and otherwise healthy. It showed that Vorasidenib delays disease progression in grade 2 glioma with an IDH mutation by an average of 27.7 months, compared to 11.1 months for those taking a placebo. Additionally, vorasidenib delayed the need for the next treatment.
Patients can now access vorasidenib the UK on compassionate grounds.
If you would like to access vorasidenib your request will need to come from a treating UK healthcare professional directly.
As a pharmaceutical company, Servier is bound by the Association of the British Pharmaceutical Industry (ABPI) Code of Practice which stipulates that it cannot discuss personal medical matters with patients or their families. Therefore, Servier advises a patient to consult with their treating healthcare professional who may contact the Servier Medical Information department directly should they have any queries regarding access to Vorasidenib and these will be addressed appropriately.